TAF1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL618659	0.67	7/20
SCHEMBL616163	0.64	6/20
Bi-2536 (SCHEMBL372489)	1.00	5/20
Bi-2536 (SCHEMBL614114)	1.00	5/20
SCHEMBL376236	0.88	5/20
SCHEMBL375825	0.83	5/20
SCHEMBL376040	0.83	5/20
SCHEMBL376093	0.81	5/20
SCHEMBL376152	0.81	5/20
SCHEMBL1202930	0.79	5/20
SCHEMBL376142	0.79	5/20
SCHEMBL376312	0.79	5/20
SCHEMBL376178	0.78	5/20
SCHEMBL376216	0.77	5/20
SCHEMBL376225	0.77	5/20
SCHEMBL376568	0.77	5/20
SCHEMBL384005	0.77	5/20
SCHEMBL375746	0.76	5/20
SCHEMBL375952	0.76	5/20
SCHEMBL376153	0.75	5/20

Clinical trials — most relevant to TAF1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder	PHASE2/PHASE3	RECRUITING
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma	PHASE1	WITHDRAWN
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Spironolactone and XPB-1 Integrity in the TFIIH Complex	nan	ENROLLING_BY_INVITATION
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Immune Interactions in Severe Asthma	nan	COMPLETED
Telomere and Telomerase	nan	WITHDRAWN
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients	nan	ACTIVE_NOT_RECRUITING
Amyotrophic Lateral Sclerosis (ALS) Families Project	nan	RECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults	nan	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Identification of New FTLD Genes	nan	UNKNOWN
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome	nan	RECRUITING
Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TAF1 binder may also engage these)

Protein	Name	Similarity
Q80UV9	—	1.000	Q80UV9 →
TAF1L	Transcription initiation factor TFIID subunit 1-like	0.995	landscape →
Q60544	—	0.994	Q60544 →
P49140	—	0.978	P49140 →
Q8K2L8	—	0.977	Q8K2L8 →
Q9H8E8	—	0.977	Q9H8E8 →
Q3UJB0	—	0.976	Q3UJB0 →
Q4KKX4	—	0.975	Q4KKX4 →
Q8CID0	—	0.975	Q8CID0 →
P17863	—	0.974	P17863 →
Q80TJ7	—	0.974	Q80TJ7 →
SF3B2	Splicing factor 3B subunit 2	0.973	landscape →
Q5R6Y9	—	0.973	Q5R6Y9 →
Q58A65	—	0.973	Q58A65 →
F1R7R1	—	0.973	F1R7R1 →
Q3KR73	—	0.973	Q3KR73 →
O88974	—	0.973	O88974 →
Q8R2T8	—	0.973	Q8R2T8 →
Q4VGL6	—	0.972	Q4VGL6 →
A2RSY1	—	0.972	A2RSY1 →
O54828	—	0.972	O54828 →
Q8N5Y2	—	0.972	Q8N5Y2 →
Q5XJV7	—	0.972	Q5XJV7 →
SAP30BP	SAP30-binding protein	0.972	landscape →
Q8WYQ5	—	0.972	Q8WYQ5 →
Q9EQM6	—	0.972	Q9EQM6 →
Q8BZR9	—	0.972	Q8BZR9 →
Q6DEZ2	—	0.972	Q6DEZ2 →
Q8QG78	—	0.972	Q8QG78 →
Q53F19	—	0.971	Q53F19 →